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Background: The Oxfordshire Community Stroke Project (OCSP) classification is a simple stroke classification system
with value in predicting clinical outcomes. We investigated whether and how the addition of OCSP classification to
the Safe Implementation of Thrombolysis in Stroke (SITS) symptomatic intracerebral hemorrhage (SICH) risk score
improved the predictive performance.
Methods: We constructed an extended risk score by adding an OCSP component, which assigns 3 points for total
anterior circulation infarcts, 0 point for partial anterior circulation infarcts or lacunar infarcts. Patients with posterior
circulation infarcts were assigned an extended risk score of zero. We analyzed prospectively collected data from 4
hospitals to compare the predictive performance between the original and the extended scores, using area under
the receiver operating characteristic curve (AUC) and net reclassification improvement (NRI).
Results: In a total of 548 patients, the rates of SICH were 7.3% per the National Institute of Neurological Diseases and
Stroke (NINDS) definition, 5.3% per the European-Australasian Cooperative Acute Stroke Study (ECASS) II, and 3.5% per
the SITS-Monitoring Study (SITS-MOST). Both scores effectively predicted SICH across all three definitions. The extended
score had a higher AUC for SICH per NINDS (0.704 versus 0.624, P = 0.015) and per ECASS II (0.703 versus 0.612,
P = 0.016) compared with the SITS SICH risk score. NRI for the extended risk score was 22.3% (P = 0.011) for SICH per
NINDS, 21.2% (P = 0.018) per ECASS II, and 24.5% (P = 0.024) per SITS-MOST.
Conclusions: Incorporation of the OCSP classification into the SITS SICH risk score improves risk prediction for
post-thrombolysis SICH.Background
Thrombolytic therapy with intravenous tissue plasmino-
gen activator (tPA) for acute ischemic stroke increases
the risk of symptomatic intracerebral hemorrhage
(SICH) [1]. Factors associated with SICH include older
age, higher baseline National Institutes of Health Stroke
Scale (NIHSS) score, elevated blood glucose, prior anti-
platelet use, presence of atrial fibrillation, congestive
heart failure, renal impairment, and early ischemic
changes on pretreatment brain imaging [2]. Several risk
score models incorporating these potential predictors* Correspondence: yuwchen@gmail.com
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unless otherwise stated.have been constructed to determine the risk of tPA-
associated SICH [3-9]. Although the discriminatory
abilities of such models appear good, there may be room
for further improvement.
Stroke territory may help estimate the risk of post-
thrombolysis hemorrhagic transformation because poster-
ior circulation stroke might be associated with a low risk
of SICH [10,11]. The concept was first implied in the
Hemorrhage After Thrombolysis (HAT) score [4], in
which the presence of hypodensity in middle cerebral
artery territory on computed tomography (CT) denotes an
anterior circulation stroke. No risk prediction models have
yet explicitly incorporated stroke territory. However, using
neuroimaging study to determine stroke territory may not
be applicable or timely in emergency settings. Even mag-
netic resonance imaging (MRI) detected acute lesions intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Risk scoring systems of the SITS SICH risk score
and the extended risk score
No. of points




Aspirin + clopidogrel 3 3
Aspirin monotherapy 2 2
NIHSS ≥13 2 2
NIHSS 7-12 1 1
Blood glucose ≥180 mg/dL 2 2
Age ≥72 y 1 1
Systolic blood pressure ≥146 mm Hg 1 1
Weight ≥95 kg 1 1
Onset-to-treatment time ≥180 min 1 1
History of hypertension 1 1
Total anterior circulation infarct N/A 3
Maximal total points 12 15*
N/A indicates not applicable; SICH: symptomatic intracerebral hemorrhage;
SITS: the Safe Implementation of Thrombolysis in Stroke.
*Patients with posterior circulation infarcts were assigned an extended risk
score of zero, irrespective of their original SITS SICH risk scores.
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within 3 hours after symptom onset [12].
The Oxfordshire Community Stroke Project (OCSP)
classification, based on clinical syndromes alone, can pre-
dict the site and size of infarct on CT in patients with
established or hyperacute ischemic stroke [13,14]. In a
previous study [15], we demonstrated that the OCSP clas-
sification could help evaluate the risk of post-thrombolysis
SICH. We therefore examined whether and how the




We analyzed data pooled from 4 hospital-based stroke
registries in Taiwan (National Cheng Kung University Hos-
pital, Chi-Mei Medical Center, Chia-Yi Christian Hospital,
and Landseed Hospital) [16]. Consecutive stroke patients
treated with intravenous tPA within 3 hours of symptom
onset between January 2007 and June 2012 were identified.
Eligibility for tPA treatment was determined following the
guidelines of the American Heart Association [17], and in-
cluded off-label use (age >80 or NIHSS score >25). Variable
dosing in the range of 0.6 to 0.9 mg/kg is recommended
according to the current Taiwan guidelines [18]. Different
treatment regimens were used in the study sites. At the
Chi-Mei Medical Center and the Landseed Hospital, the
dose was fixed at 0.9 mg/kg. At the Chia-Yi Christian
Hospital, the dose was initially set at 0.9 mg/kg and was
changed to 0.8 mg/kg after August 2010. At the National
Cheng Kung University Hospital, the dose was initially set
at 0.7 mg/kg and was altered to 0.9 mg/kg after July 2009.
Stroke severity was assessed by the NIHSS at baseline and
at discharge. All patients underwent CT or MRI between
24 and 36 hours after thrombolysis and additional scans in
case of clinical deterioration. The official neuroradiology
reports were used to determine the presence and size of
visible hypodensity on initial head CT scan and the pre-
sence or absence of intracerebral hemorrhage (ICH) on
follow-up scans. The study protocol was approved by the
Landseed Institutional Review Board (IRB), National Cheng
Kung University Hospital IRB, Chi-Mei Medical Center
IRB, and Chia-Yi Christian Hospital IRB, respectively.
Research coordinators in each site extracted the parts of
medical charts recording the neurological symptoms and
signs before the administration of intravenous tPA. Two
board-certified neurologists (CSW and LCH), who were
blinded to neuroimaging findings and risk scores of each
patient, independently examined the abstracted records
and performed the clinical classification [19]. Patients
were classified as having total anterior circulation infarcts
(TACI), partial anterior circulation infarcts (PACI), poste-
rior circulation infarcts (POCI), or lacunar infarcts (LACI)
based on their maximal neurological deficits before theinitiation of thrombolytic therapy. Undetermined stroke
syndrome was classified as “uncertain”. Discrepancies
were resolved by including a third board-certified neurolo-
gist (YCH), or classified as uncertain when all three
disagreed with each other.
Outcome measures
Primary outcome was the occurrence of SICH following
intravenous tPA treatment. Because SICH rates are sub-
ject to the definition of SICH, we applied three definitions.
SICH per the National Institute of Neurological Diseases
and Stroke (NINDS) is defined as any neurological wor-
sening (NIHSS ≥1) within 36 hours of tPA administration
that is attributed to ICH verified by CT or MRI [1]. SICH
per the European-Australasian Cooperative Acute Stroke
Study (ECASS) II is defined as any type of ICH on any
posttreatment imaging after the start of thrombolysis and a
neurological deterioration of ≥4 points on the NIHSS from
baseline, or from the lowest value within 7 days, or leading
to death [20]. SICH per the Safe Implementation of
Thrombolysis in Stroke - Monitoring Study (SITS-MOST)
is defined as a local or remote type 2 parenchymal hemor-
rhage on the 22- to 36-hour post-treatment CT scan asso-
ciated with a neurological deterioration of ≥4 points on the
NIHSS or leading to death [21].
Calculation of the risk score
We calculated the Safe Implementation of Thrombolysis
in Stroke (SITS) SICH risk score (Table 1) for each pa-
tient [7]. The decision to apply this particular risk score
was based on the facts that it was derived from the
Table 2 Characteristics of the study patients
n = 548
Demographics
Age, mean (SD) 67 (12)
Male, n (%) 345 (63.0)
Medical history, n (%)
Hypertension 406 (74.1)
Diabetes mellitus 177 (32.3)
Hyperlipidaemia 303 (55.3)
Atrial fibrillation 169 (30.8)
Congestive heart failure 37 (6.8)
Prior stroke/TIA 116 (21.2)




Baseline NIHSS score, median (IQR) 13 (8–20)
Body weight, mean (SD), kg 65 (13)
Systolic blood pressure, mean (SD), mm Hg 161 (30)
Glucose, mean (SD), mmol/L 8.49 (3.72)
Platelet count, mean (SD), ×109/L 215 (70)
Actual tPA dose, median (IQR), mg/kg 0.86 (0.75–0.91)
OTT, median (IQR), min 125 (100–155)






IQR indicates interquartile range; LACI: lacunar infarct; NIHSS: National
Institutes of Health Stroke Scale; OCSP: Oxfordshire Community Stroke Project;
OTT: onset-to-treatment time; PACI: partial anterior circulation infarcts;
POCI: posterior circulation infarcts; SD: standard deviation; TACI: total anterior
circulation infarcts; TIA: transient ischemic attack; tPA: tissue-type
plasminogen activator.
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tions of SICH of interest, and has been validated in our
study population [16]. The SITS SICH risk score in-
cludes 9 variables with different weights (age, baseline
NIHSS score, glucose, systolic blood pressure, body
weight, time from stroke onset to thrombolysis, history
of hypertension, aspirin monotherapy, and combined
use of aspirin and clopidogrel) and ranges from 0 to 12
points [7].
We constructed an extended SITS SICH risk score
(Table 1) by incorporating an OCSP classification compo-
nent. In light of a finding that TACI increased sixfold the
risk of SICH per ECASS II (after adjustment for age, glu-
cose, and antiplatelet use before admission) [15], initially
we assigned 3 points to TACI and 0 point to PACI or LACI
in the OCSP classification component. Furthermore, con-
sidering the low risk of SICH in posterior circulation stroke
[10,11], patients with POCI were assigned an extended risk
score of zero, irrespective of their original SITS SICH risk
scores. After examining the discrimination ability of dif-
ferent weighting of TACI using the area under the receiver
operating characteristic curve (AUC) (Additional file 1:
Table S1), we eventually constructed the 15-point extended
risk score as described above.
Statistical analysis
Continuous variables were summarized as mean ± SD or
median (interquartile range), and categorical variables as
counts and percentages. We performed separate univa-
riate logistic regressions for the original and the ex-
tended risk score to determine the odds ratios per point
increase of the score. The model fit was judged by the
Hosmer–Lemeshow goodness-of-fit statistic. The dis-
criminatory ability of the extended score was evaluated
by the AUC, and compared using the DeLong method
[22]. Bootstrap resampling (1000 replicates) was used to
estimate confidence intervals for the AUC.
We examined risk reclassification from strata of the SITS
SICH risk score to those of the extended risk score by
cross tabulation. For practical purposes, we stratified the
SITS SICH risk score into 3 categories: low (0 to 2 points),
average (3 to 5 points), and elevated risk (≥6 points). The
same cutoffs were used in the SITS SICH risk score study
[7], but we collapsed strata of 6 to 8 points and ≥9 points
into one group. To align the thresholds for defining risk
categories, the extended risk score was categorized into
low (0 to 3 points), average (4 to 7 points), and elevated
risk (≥8 points). We used the net reclassification improve-
ment (NRI), calculated as [proportion of all SICH events
reclassified at higher risk – proportion reclassified at lower
risk] – [proportion of all nonevents reclassified at higher
risk – proportion reclassified at lower risk] [23], to assess
the incremental effect of adding the OCSP classification
component. Two tailed P values <0.05 were consideredstatistically significant. Statistical analyses were performed
using MedCalc 12.5.0 (MedCalc Software bvba, Ostend,
Belgium) or Stata 11 (StataCorp, College Station, Texas).
Results
A total of 548 thrombolyzed patients were included in the
study. Table 2 shows the characteristics. The rates of SICH
were 7.3% per the NINDS definition, 5.3% per ECASS II,
and 3.5% per SITS-MOST. The agreement of the OCSP
classification was moderate (κ = 0.583) between the two
initial assessors (Additional file 1: Table S2).
Both the SITS SICH risk score and the extended risk
score reasonably predicted the occurrence of SICH and
were well calibrated (Table 3). The AUCs were higher for
the extended risk score than for the SITS SICH risk score
Table 3 Comparison of prediction performance between the SITS SICH risk score and the extended risk score










SITS SICH risk score 1.35 (1.11-1.64) 1.72 0.887 0.624 (0.533-0.714) - - - -
Extended risk score 1.30 (1.15-1.46) 4.30 0.745 0.704 (0.618-0.791) 0.081 0.015 22.3% 0.011
SICH per ECASS II
SITS SICH risk score 1.34 (1.08-1.68) 3.25 0.661 0.612 (0.503-0.721) - - - -
Extended risk score 1.30 (1.13-1.49) 4.23 0.752 0.703 (0.611-0.796) 0.091 0.016 21.2% 0.018
SICH per SITS-MOST
SITS SICH risk score 1.49 (1.14-1.94) 2.10 0.835 0.678 (0.563-0.793) - - - -
Extended risk score 1.33 (1.12-1.58) 6.45 0.488 0.723 (0.622-0.824) 0.044 0.293 24.5% 0.024
AUC indicates area under the receiver operating characteristic curve; CI: confidence intervals; ECASS: The European-Australasian Cooperative Acute Stroke Study;
NINDS: National Institute of Neurological Disorders and Stroke; SICH: symptomatic intracerebral hemorrhage; SITS-MOST: the Safe Implementation of Thrombolysis
in Stroke - Monitoring Study.
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per NINDS (P = 0.015) and per ECASS II (P = 0.016).
Reclassification of patients improved with an NRI of
22.3% (P = 0.011) for SICH per NINDS, 21.2% (P = 0.018)
per ECASS II, and 24.5% (P = 0.024) per SITS-MOST
(Additional file 1: Table S3 to S5). Given the designated
risk strata, the SITS SICH risk score categorized 19% of
patients at low risk, 66% at average risk, and 15% at
elevated risk, whereas the corresponding values by the
extended risk score were 37%, 44%, and 19%.Discussion
We demonstrated that incorporation of the OCSP clas-
sification into the SITS SICH risk score significantly im-
proved the performance in predicting SICH in our study
population. The extended risk score reasonably predicted
SICH across the three definitions with good calibration. A
substantial proportion of patients without SICH were re-
classified into lower risk category (NRI for these patients
was about 14% across the three definitions of SICH).
Overall, the extended risk score moved an additional 18%
(37% minus 19%) of patients to the low risk category, and
46% (168 of 362) patients with average risk (3 to 5 points
according to the SITS SICH risk score) were reclassified
(Additional file 1: Table S3 to S5).
The improved discriminatory ability of the extended
risk score is clinically useful and might facilitate throm-
bolytic treatment in acute ischemic stroke. Notably,
many emergency physicians were unwilling to provide
thrombolysis for acute ischemic stroke in fear of SICH
[24]. In Taiwan, perceived risk of SICH among emer-
gency physicians, neurologists, and patients was a major
barrier to implement thrombolytic treatment [25]. Risk
prediction models that could correctly identify patients
at low SICH risk after thrombolysis are of great benefitto stroke patients because they help remove the psycho-
logical barriers to administering tPA.
Studies show that patients with posterior circulation
stroke are unlikely to develop SICH or hemorrhagic trans-
formations [10,11]. Therefore in our study the patients
with POCI were assigned an extended risk score of zero.
A potential mechanism underlying the low incidence of
SICH in posterior circulation stroke is the infrequent
permeability derangements detected on pretreatment MRI
[26]. Permeability derangements, which indicate blood–
brain barrier disruption in ischemic fields, increased the
propensity for hemorrhagic transformation in stroke pa-
tients treated with either recanalization therapy or conser-
vative care [27]. Another possible mechanism is better
collaterals in the territory of the posterior cerebral artery
than that of the middle cerebral artery [28]. Patients with
good collateral circulation might be less vulnerable to
SICH after recanalization therapy [29,30]. Additionally,
the size of ischemic brain tissue was associated with SICH
after intravenous thrombolysis [31,32]. The small lesion
volume in infratentorial strokes as compared to supraten-
torial strokes might partly explain the low incidence of
SICH in patients with POCI.
Because the volume of the affected brain tissue is gene-
rally correlated with clinical stroke severity, models for
predicting post-thrombolysis SICH usually included the
NIHSS or the less commonly used Canadian Neurological
Scale as a predictor [3-9]. However, patients with right
hemisphere strokes may have a low NIHSS score despite a
substantial lesion volume [33]. Consequently, patients
with right hemisphere nonlacunar strokes would have a
higher risk of post-thrombolysis hemorrhage than those
with left hemisphere strokes and similar NIHSS scores
[34]. In contrast, the OCSP classification in the early hours
of ischemic stroke correlated well with infarct size [14].
Without the assessment bias between hemispheres, the
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predicting SICH risk.
Although the OCSP classification generally corre-
sponded well to the radiological findings, the sensitivity
and specificity were different among the four OCSP cat-
egories. Using lesion topography on diffusion-weighted
MRI as the diagnostic standard, the likelihood of correct
classification was low for PACI and LACI, whereas high
for TACI and POCI [35]. Therefore, we did not differen-
tiate patients with PACI from those with LACI in de-
signing the extended risk score. Theoretically, a prediction
model combining imaging findings and clinical factors
could improve the prediction of SICH. A recent study
indicated that the blood Sugar, Early infarct signs, hy-
perDense cerebral artery sign, Age, and NIHSS (SEDAN)
score [6] had the highest predictive power among the
existing risk prediction scores [36]. Our previous study
also found that the HAT score performed well [16]. How-
ever, the interpretation of early infarct signs or hyperdense
cerebral artery sign requires considerable radiological
expertise, which may not be feasible in settings where
neuroradiologists are not available on a 24/7 basis [37]. In
addition to indicating an anterior circulation infarct, the
appearance of early infarct signs on CTalso hints at longer
elapsed time since stroke onset [38]. The inclusion of total
anterior circulation infarct and the onset-to-treatment
time, which is a component of the SITS SICH risk score,
in our revised risk score offers a clinical counterpart to
the radiological findings of early infarct signs. Although
the SITS SICH risk score in conjunction with the OCSP
classification seems more complex, it provides an alterna-
tive when the local radiological expertise is limited. In par-
ticular, the OCSP classification could be easily and reliably
determined using a standard symptom list [39].
Methods of model assessment should depend on the
intended use of the model. Intravenous thrombolysis
should not be withheld for an otherwise eligible patient
simply because of high anticipated risk of SICH. The
demonstrated improvement in classification performance
in the extended risk score should be used only to better
comprehend the risk associated with thrombolytic the-
rapy. In particular, reclassification performance is sensitive
to the number of clinically relevant risk categories, and
the OCSP classification renders applying the risk scores
largely unnecessary in patients with POCI.
Awareness of the applications and potential limitations
of the risk scores will aid the clinicians in daily clinical
decision making. Patients and their family could be bet-
ter informed of the risk of SICH before making a shared
treatment decision with their physicians. Those at high
risk of SICH may benefit from more intensive monito-
ring, such as blood pressure and blood glucose. Another
potential use of the risk scores is for case-mix adjust-
ment in light of the fact that post-thrombolysis SICHmight be used to measure performance of acute stroke
care [40].
Our study has limitations. First, the OCSP syndromes
were assessed based on medical records, rather than per-
sonal examination. Although the interrater agreement in
the clinical classification of syndromes was moderate, the
accuracy of classification might be compromised. Further
studies with prospective OCSP classification are needed to
confirm the clinical implications of our findings. Second,
the number of SICH events was small, which precluded
multivariable analyses, such as reweighting the predictors
of the SITS SICH risk score. The limited number of events
might also explain the failure to show superior discrimi-
nation (higher AUC) of the extended risk score in pre-
dicting SICH per the SITS-MOST definition. Third, a
proportion of our patients were treated with a lower dose
of intravenous tPA. Whether the prediction performance
of risk models is subject to dosage remains to be explored.
Finally, our study should be viewed as hypothesis generat-
ing. Potential patient selection bias could impact the
model performance. Further validation is needed to
strengthen generalizability of our findings.
Conclusions
Incorporating the OCSP classification of stroke syndromes
to the SITS SICH risk score could improve the risk pre-
diction for post-thrombolysis SICH. Further studies to
evaluate the performance of the extended risk score on
large cohorts are warranted.
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